Fulcrum Gains Momentum After Agios Trial Miss

Fulcrum Therapeutics rises as Agios’ RISE UP trial falls short. Analysts say results reduce competition in sickle cell disease and strengthen Fulcrum’s position ahead of new PIONEER data.